Rhenman & Partners Asset Management AB lessened its stake in Revance Therapeutics Inc (NASDAQ:RVNC) by 4.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 193,181 shares of the biopharmaceutical company’s stock after selling 10,000 shares during the period. Rhenman & Partners Asset Management AB owned approximately 0.52% of Revance Therapeutics worth $3,889,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Bank of America Corp DE lifted its holdings in shares of Revance Therapeutics by 295.8% in the 2nd quarter. Bank of America Corp DE now owns 120,757 shares of the biopharmaceutical company’s stock worth $3,315,000 after acquiring an additional 90,248 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Revance Therapeutics by 26.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 2,464,617 shares of the biopharmaceutical company’s stock worth $61,245,000 after acquiring an additional 519,938 shares during the last quarter. Capital International Investors bought a new stake in shares of Revance Therapeutics in the 3rd quarter worth approximately $8,076,000. Allianz Asset Management GmbH lifted its holdings in shares of Revance Therapeutics by 8.0% in the 3rd quarter. Allianz Asset Management GmbH now owns 85,377 shares of the biopharmaceutical company’s stock worth $2,122,000 after acquiring an additional 6,311 shares during the last quarter. Finally, Federated Investors Inc. PA lifted its holdings in shares of Revance Therapeutics by 4.6% in the 3rd quarter. Federated Investors Inc. PA now owns 83,810 shares of the biopharmaceutical company’s stock worth $2,083,000 after acquiring an additional 3,680 shares during the last quarter. Hedge funds and other institutional investors own 92.65% of the company’s stock.

NASDAQ:RVNC opened at $17.11 on Monday. Revance Therapeutics Inc has a 52 week low of $16.56 and a 52 week high of $34.55. The firm has a market cap of $632.90 million, a P/E ratio of -4.27 and a beta of 0.86.

A number of equities research analysts have recently weighed in on the stock. Cantor Fitzgerald restated a “buy” rating and issued a $50.00 price objective on shares of Revance Therapeutics in a report on Thursday, November 1st. Zacks Investment Research upgraded shares of Revance Therapeutics from a “hold” rating to a “strong-buy” rating and set a $20.00 price objective for the company in a report on Tuesday, January 22nd. BidaskClub upgraded shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, October 16th. Mizuho restated a “buy” rating on shares of Revance Therapeutics in a report on Friday, January 18th. Finally, ValuEngine upgraded shares of Revance Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, December 5th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $44.88.

COPYRIGHT VIOLATION WARNING: This piece was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://theolympiareport.com/2019/02/11/rhenman-partners-asset-management-ab-cuts-holdings-in-revance-therapeutics-inc-rvnc.html.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.

See Also: Channel Trading

Want to see what other hedge funds are holding RVNC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revance Therapeutics Inc (NASDAQ:RVNC).

Institutional Ownership by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.